Two distinct clinical courses of renal involvement in rheumatoid patients with AA amyloidosis

Journal of Rheumatology

Volumn 33, Issue 8, 2006, Pages 1482-1487

  Uda, Hiroshi ^a,b   Yokota, Akira ^c   Kobayashi, Kumiko ^c   Miyake, Tadao ^c   Fushimi, Hiroaki ^c   Maeda, Akira ^d   Saiki, Osamu ^a,b  

^a Bell Land General Hospital   (Japan)

^b Osaka Prefecture University   (Japan)

^c OSAKA GENERAL MEDICAL CENTER   (Japan)

^d YUKIOKA HOSPITAL   (Japan)

Author keywords

Amyloidosis; Biopsy; Creatinine; Kidney failure; Rheumatoid arthritis

Indexed keywords

AMYLOID A PROTEIN; AZATHIOPRINE; CYCLOSPORIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GOLD; METHOTREXATE; MINOCYCLINE; PENICILLAMINE; PREDNISOLONE; SALAZOSULFAPYRIDINE;

ADULT; AGED; AMYLOIDOSIS; ARTICLE; CLINICAL ARTICLE; DISEASE COURSE; DUODENUM BIOPSY; FEMALE; GLOMERULUS; HEMODIALYSIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KIDNEY AMYLOIDOSIS; KIDNEY BIOPSY; KIDNEY FAILURE; KIDNEY FUNCTION; LOW DRUG DOSE; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RHEUMATOID ARTHRITIS;

AMYLOIDOSIS; ARTHRITIS, RHEUMATOID; BLOOD UREA NITROGEN; CREATININE; DUODENUM; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY; KIDNEY DISEASES; KIDNEY FUNCTION TESTS; KIDNEY GLOMERULUS; PROSPECTIVE STUDIES; SERUM AMYLOID A PROTEIN; SURVIVAL RATE;

EID: 33746765644     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Falk RH, Comenzo RL, Skinner M, Falk R. The systemic amyloidoses. N Engl J Med 1997;337:898-909.
2. Husby G, Stenstad T, Magnus JH, Sletten K, Nordvag BY, Marhaug G. Interaction between circulating amyloid fibril protein precursors and extracellular tissue matrix components in the pathogenesis of systemic amyloidosis. Clin Immunol Immunopathol 1994;70:2-9.
3. Cunnane G. Amyloid proteins in pathogenesis of AA amyloidosis. Lancet 2001;358:24-5.
4. Sipe J, Cohen A. Review: History of the amyloid fibril. J Struct Biol 2000;130:88-98.
5. Cunnane G, Grehan S, Geoghegan S, et al. Serum amyloid A in the assessment of early inflammatory arthritis. J Rheumatol 2000;27:58-63.
6. Morie AG, Robert AK. Secondary systemic amyloidosis: response and survival in 64 patients. Medicine 1991;70:246-56.
7. Dhillon V, Woo P, Isenberg D. Amyloidosis in the rheumatic diseases. Ann Rheum Dis 1989;48:696-701.
8. Paydas S. Report on 59 patients with renal amyloidosis. Int Urol Nephrol 1999;31:619-31.
9. Van der Hem GK, van Rijswijk MH. Amyloidosis. In: Cameron S, Davidson AM, Grünfeld JP, et al, editors. Oxford textbook of clinical nephrology. Oxford: Oxford University Press; 1992:545-61.
10. Gomez-Casanovas E, Sanmartí R, Solé M, Cañete JD, Muñoz-Gómez J. The clinical significance of amyloid fat deposits in rheumatoid arthritis: a systematic long-term followup study using abdominal fat aspiration. Arthritis Rheum 2001;44:66-72.
11. Heikki JH, Markku MK, Jukka TM, Amos IP. Renal biopsy findings and clinicopathologic correlations in rheumatoid arthritis. Arthritis Rheum 1995;38:242-7.
12. Looi LM, Cheah PL. Histomorphological patterns of renal amyloidosis: a correlation between histology and chemical type of amyloidosis. Hum Pathol 1997;28:847-9.
13. Tuglular S, Yalcinkaya F, Paydas S, et al. A retrospective analysis for aetiology and clinical findings of 287 secondary amyloidosis cases in Turkey. Nephrol Dial Transplant 2002;17:2003-5.
14. Bohle A, Wehrmann M, Eissele R, von Gise H, Mackensen-Haen S, Muller C. The long-term prognosis of AA and AL renal amyloidosis and the pathogenesis of chronic renal failure in renal amyloidosis. Pathol Res Pract 1993;189:316-31.
15. Gillmore JD, Lovat LB, Persey MR, Pepys MB, Hawkins PN. Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet 2001;358:24-9.
16. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
17. Glenner GG. Amyloid deposits and amyloidosis: the beta-fibrilloses. N Engl J Med 1980;302:1283-92.
18. Steinbrocker O, Traeger CH, Batterman RC. Therapeutic criteria in rheumatoid arthritis. JAMA 1949;140:659-62.
19. Couverchel L, Maugars Y, Prost A. Outcomes of thirty-four rheumatoid arthritis patients with renal amyloidosis, including twelve given alkylating agents. Rev Rhum Engl Ed 1995;62:79-85.
20. Falck HM, Törnroth T, Wegelius O. Predominantly vascular amyloid deposition in the kidney in patients with minimal or no proteinuria. Clin Nephrol 1983;19:137-42.
21. Duston MA, Skinner M, Meenan RF, Cohen AS. Sensitivity, specificity, and predictive value of abdominal fat aspiration for the diagnosis of amyloidosis. Arthritis Rheum 1990;33:301-2.
22. Brandt K, Cathcart ES, Cohen AS. A clinical analysis of the course and prognosis of forty-two patients with amyloidosis. Am J Med 1968;44:955-69.
23. Looi LM. Histomorphological variations in systemic AA amyloidosis: clues of AA protein polymorphism. Histopathol 1989;14:111-20.
24. Yamada T, Okuda Y, Takasugi K, et al. An allele of serum amyloid AI associated with amyloidosis in both Japanese and Caucasians. Amyloid 2003;10:7-11.
25. Dikman SH, Kahn T, Gribetz D, Churg J. Resolution of renal amyloidosis. Am J Med 1977;63:430-3.
26. Lowenstein J, Gallo G. Remission of the nephrotic syndrome in renal amyloidosis. New Engl J Med 1970;282:128-32.
27. Elkayam O, Hawkins PN, Lachmann H, Yaron M, Caspi D. Rapid and complete resolution of proteinuria due to renal amyloidosis in a patient with rheumatoid arthritis treated with infliximab. Arthritis Rheum 2002;46:2571-3.
28. Gottenberg JE, Merle-Vincent F, Bentaberry F, et al. Anti-tumor necrosis factor alpha therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritis: a followup report of tolerability and efficacy. Arthritis Rheum 2003;48:2019-24.